CNTY-813 is an iPSC-derived islet cell replacement therapy engineered with Allo-Evasion™ 5.0 for patients with type 1 diabetes; on track for IND submission in 4Q 2026 ...AmericanDiabetesAssociation).
His younger brother and dad have Type 1 diabetes so they’ve always needed to pack enough supplies and medication for any situation.Article content ... Her younger son was diagnosed with Type 1 diabetes at 13 months.
Comprising five days of educational and informational sessions targeting the diabetes marketplace, ATTD 2026 boasted 90 exhibitors showcasing their latest products and technologies.
High-dose vitamin D supplements could help reduce diabetes risk among certain groups, according to new research from Tufts University... An earlier study showed no significant reduction in diabetes risk ...
The event concluded with an introductory tour of the system, emphasizing its actual launch within medical centers—a step described as a qualitative leap in diabetes management across Libya.